Literature DB >> 11324765

Radiosurgery for brain metastases from primary lung carcinoma.

R Hoffman1, P K Sneed, M W McDermott, S Chang, K R Lamborn, E Park, W M Wara, D A Larson.   

Abstract

PURPOSE: Brain metastases are a common problem in patients with lung cancer. This retrospective review was performed to describe the efficacy and toxicity of stereotactic radiosurgery for brain metastases from lung carcinoma and to evaluate prognostic factors for survival. PATIENTS AND METHODS: A retrospective review was performed of 113 patients with the diagnosis of lung carcinoma who underwent radiosurgery with or without whole-brain radiotherapy for management of newly diagnosed or recurrent, single, or multiple brain metastases from 1991 through 1998 at the University of California, San Francisco. Freedom from progression and survival were measured from the date of radiosurgery and estimated using the Kaplan-Meier method. Prognostic factors were evaluated with the log-rank test and Cox proportional hazards models.
RESULTS: The median patient age at the time of radiosurgery was 59 years (range, 37-82 years), and the median Karnofsky performance score was 90 (range, 50-100). The median survival time from radiosurgery was 12.0 months overall, 13.9 months for 41 patients treated with radiosurgery alone initially, 14.5 months for 19 patients treated with radiosurgery and whole-brain radiotherapy initially, and 10.0 months for 53 patients with recurrent brain metastases. Among newly diagnosed patients, multivariate analysis showed that improved survival was associated with absence of extracranial metastases and fewer brain metastases. Among patients with recurrent brain metastases, improved survival was associated with higher Karnofsky performance score, control of the primary tumor, and fewer metastases. Measured by lesion, 1-year local freedom from progression probabilities were 81% for radiosurgery alone, 86% for radiosurgery and whole-brain radiotherapy, and 65% for radiosurgery performed after recurrence. In patients with newly diagnosed brain metastases, there was a significantly greater risk of developing subsequent brain metastases and of worse overall brain freedom from progression after radiosurgery alone versus radiosurgery and whole-brain radiotherapy. One-year brain freedom from progression probabilities were 13% without salvage therapy and 62% with salvage therapy in the 41 patients treated initially with radiosurgery alone, versus 67% without salvage therapy and 89% with salvage therapy in the 19 patients treated initially with radiosurgery plus whole-brain radiotherapy. DISCUSSION: Radiosurgery is an effective therapy for selected patients with newly diagnosed or recurrent brain metastases from lung carcinoma. Initial whole-brain radiotherapy with radiosurgery appears to improve brain control but not survival. Prospective, randomized trials are needed to further investigate the role of radiosurgery with and without whole-brain radiotherapy for brain metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11324765

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  18 in total

Review 1.  Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options.

Authors:  Meysam Yousefi; Tayyeb Bahrami; Arash Salmaninejad; Rahim Nosrati; Parisa Ghaffari; Seyed H Ghaffari
Journal:  Cell Oncol (Dordr)       Date:  2017-09-18       Impact factor: 6.730

Review 2.  Neurosurgical management of patients with brain metastasis.

Authors:  Mustafa Aziz Hatiboglu; Kerime Akdur; Raymond Sawaya
Journal:  Neurosurg Rev       Date:  2018-07-29       Impact factor: 3.042

Review 3.  Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy.

Authors:  Martin Kocher; Andrea Wittig; Marc Dieter Piroth; Harald Treuer; Heinrich Seegenschmiedt; Maximilian Ruge; Anca-Ligia Grosu; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2014-04-09       Impact factor: 3.621

4.  Evaluation of results of linac-based radiosurgery for brain metastases from primary lung cancer.

Authors:  Dorota Jezierska; Krystyna Adamska; Włodzimierz Liebert
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-03

Review 5.  Treatment options for brain metastases in patients with non-small-cell lung cancer.

Authors:  Sadaf Taimur; Martin J Edelman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

6.  Chemosensitized radiosurgery for recurrent brain metastases.

Authors:  David Roberge; Luis Souhami; Marie-Andrée Fortin; Jean-François Pouliot
Journal:  J Neurooncol       Date:  2012-08-22       Impact factor: 4.130

7.  Repeated stereotactic radiosurgery for patients with progressive brain metastases.

Authors:  Giuseppe Minniti; Claudia Scaringi; Sergio Paolini; Enrico Clarke; Francesco Cicone; Vincenzo Esposito; Andrea Romano; Mattia Osti; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2015-09-14       Impact factor: 4.130

8.  Clinical outcomes of patients treated with a second course of stereotactic radiosurgery for locally or regionally recurrent brain metastases after prior stereotactic radiosurgery.

Authors:  Daniel H Kim; Timothy E Schultheiss; Eric H Radany; Behnam Badie; Richard D Pezner
Journal:  J Neurooncol       Date:  2013-06-28       Impact factor: 4.130

Review 9.  The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

Review 10.  The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Mario Ammirati; Charles S Cobbs; Mark E Linskey; Nina A Paleologos; Timothy C Ryken; Stuart H Burri; Anthony L Asher; Jay S Loeffler; Paula D Robinson; David W Andrews; Laurie E Gaspar; Douglas Kondziolka; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Roy A Patchell; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2009-12-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.